Last 12 months
Inside the activity.
0 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 2 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 15, 2026 Filed May 19, 2026 20:15 UTC |
Carpenter RickEVP & Chief Technology Officer
|
Tax withholdingCommon Stock | 3,277 | $12.82 | $42,011.14 |
DisclosureSEC source: 0001438133-26-000068 · wk-form4_1779221737.xml · nonDerivative · entry 6 Carpenter Rick · CIK 0001513889 · EVP & Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,582 F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:15 UTC |
Carpenter RickEVP & Chief Technology Officer
|
Exercise / conversionCommon Stock | 6,439 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000068 · wk-form4_1779221737.xml · nonDerivative · entry 5 Carpenter Rick · CIK 0001513889 · EVP & Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,859 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:15 UTC |
Carpenter RickEVP & Chief Technology Officer
|
Tax withholdingCommon Stock | 457 | $12.82 | $5,858.74 |
DisclosureSEC source: 0001438133-26-000068 · wk-form4_1779221737.xml · nonDerivative · entry 4 Carpenter Rick · CIK 0001513889 · EVP & Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,420 F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:15 UTC |
Carpenter RickEVP & Chief Technology Officer
|
Exercise / conversionCommon Stock | 898 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000068 · wk-form4_1779221737.xml · nonDerivative · entry 3 Carpenter Rick · CIK 0001513889 · EVP & Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,877 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:15 UTC |
Carpenter RickEVP & Chief Technology Officer
|
Tax withholdingCommon Stock | 732 | $12.82 | $9,384.24 |
DisclosureSEC source: 0001438133-26-000068 · wk-form4_1779221737.xml · nonDerivative · entry 2 Carpenter Rick · CIK 0001513889 · EVP & Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,979 F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:15 UTC |
Carpenter RickEVP & Chief Technology Officer
|
Exercise / conversionCommon Stock | 1,437 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000068 · wk-form4_1779221737.xml · nonDerivative · entry 1 Carpenter Rick · CIK 0001513889 · EVP & Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,711 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:12 UTC |
Hansen Shannon MarieEVP & Chief Legal Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 7,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000064 · wk-form4_1779221525.xml · derivative · entry 11 Hansen Shannon Marie · CIK 0001908267 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,335 Underlying: Common Stock · 7,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · security: Awarded on May 30, 2025 pursuant to the 2023 Plan. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F10 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2026, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F10 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2026, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:12 UTC |
Hansen Shannon MarieEVP & Chief Legal Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,097 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000064 · wk-form4_1779221525.xml · derivative · entry 10 Hansen Shannon Marie · CIK 0001908267 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,387 Underlying: Common Stock · 1,097 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · security: Awarded on May 23, 2024 pursuant to the 2023 Plan. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F8 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F8 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:12 UTC |
Hansen Shannon MarieEVP & Chief Legal Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,437 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000064 · wk-form4_1779221525.xml · derivative · entry 9 Hansen Shannon Marie · CIK 0001908267 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,437 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Awarded on May 25, 2023 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). F5 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F6 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F6 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:12 UTC |
Hansen Shannon MarieEVP & Chief Legal Officer
|
GrantCommon Stock | 1,886 | $10.90 | $20,557.40 |
DisclosureSEC source: 0001438133-26-000064 · wk-form4_1779221525.xml · nonDerivative · entry 7 Hansen Shannon Marie · CIK 0001908267 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,171 F2 · kind: The reporting person is voluntarily reporting the acquisition of shares of common stock pursuant to the Tandem Diabetes Care, Inc. Amended and Restated 2013 Employee Stock Purchase Plan (ESPP), for the ESPP purchase period of November 18, 2025, through May 15, 2026. This transaction is also exempt under Rule 16b-3(c). Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:12 UTC |
Hansen Shannon MarieEVP & Chief Legal Officer
|
Tax withholdingCommon Stock | 3,901 | $12.82 | $50,010.82 |
DisclosureSEC source: 0001438133-26-000064 · wk-form4_1779221525.xml · nonDerivative · entry 6 Hansen Shannon Marie · CIK 0001908267 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,285 F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:12 UTC |
Hansen Shannon MarieEVP & Chief Legal Officer
|
Exercise / conversionCommon Stock | 7,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000064 · wk-form4_1779221525.xml · nonDerivative · entry 5 Hansen Shannon Marie · CIK 0001908267 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,186 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:12 UTC |
Hansen Shannon MarieEVP & Chief Legal Officer
|
Tax withholdingCommon Stock | 559 | $12.82 | $7,166.38 |
DisclosureSEC source: 0001438133-26-000064 · wk-form4_1779221525.xml · nonDerivative · entry 4 Hansen Shannon Marie · CIK 0001908267 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,519 F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:12 UTC |
Hansen Shannon MarieEVP & Chief Legal Officer
|
Exercise / conversionCommon Stock | 1,097 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000064 · wk-form4_1779221525.xml · nonDerivative · entry 3 Hansen Shannon Marie · CIK 0001908267 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,078 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:12 UTC |
Hansen Shannon MarieEVP & Chief Legal Officer
|
Tax withholdingCommon Stock | 732 | $12.82 | $9,384.24 |
DisclosureSEC source: 0001438133-26-000064 · wk-form4_1779221525.xml · nonDerivative · entry 2 Hansen Shannon Marie · CIK 0001908267 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,981 F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:12 UTC |
Hansen Shannon MarieEVP & Chief Legal Officer
|
Exercise / conversionCommon Stock | 1,437 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000064 · wk-form4_1779221525.xml · nonDerivative · entry 1 Hansen Shannon Marie · CIK 0001908267 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,713 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:10 UTC |
Kyrillos Jean-ClaudeEVP & Chief Operating Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 4,038 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000062 · wk-form4_1779221403.xml · derivative · entry 4 Kyrillos Jean-Claude · CIK 0001804186 · EVP & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,077 Underlying: Common Stock · 4,038 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Awarded on May 30, 2025 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). F4 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F5 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2026, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F5 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2026, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:10 UTC |
Kyrillos Jean-ClaudeEVP & Chief Operating Officer
|
GrantCommon Stock | 434 | $10.90 | $4,730.60 |
DisclosureSEC source: 0001438133-26-000062 · wk-form4_1779221403.xml · nonDerivative · entry 3 Kyrillos Jean-Claude · CIK 0001804186 · EVP & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,105 F2 · kind: The reporting person is voluntarily reporting the acquisition of shares of common stock pursuant to the Tandem Diabetes Care, Inc. Amended and Restated 2013 Employee Stock Purchase Plan (ESPP), for the ESPP purchase period of November 18, 2025, through May 15, 2026. This transaction is also exempt under Rule 16b-3(c). Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:10 UTC |
Kyrillos Jean-ClaudeEVP & Chief Operating Officer
|
Tax withholdingCommon Stock | 2,139 | $12.82 | $27,421.98 |
DisclosureSEC source: 0001438133-26-000062 · wk-form4_1779221403.xml · nonDerivative · entry 2 Kyrillos Jean-Claude · CIK 0001804186 · EVP & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,671 F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:10 UTC |
Kyrillos Jean-ClaudeEVP & Chief Operating Officer
|
Exercise / conversionCommon Stock | 4,038 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000062 · wk-form4_1779221403.xml · nonDerivative · entry 1 Kyrillos Jean-Claude · CIK 0001804186 · EVP & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,810 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:08 UTC |
Morrison SusanEVP & Chief Admin. Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 6,923 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000060 · wk-form4_1779221291.xml · derivative · entry 10 Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,845 Underlying: Common Stock · 6,923 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · security: Awarded on May 30, 2025 pursuant to the 2023 Plan. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F9 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2026, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F9 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2026, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:08 UTC |
Morrison SusanEVP & Chief Admin. Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,097 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000060 · wk-form4_1779221291.xml · derivative · entry 9 Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,387 Underlying: Common Stock · 1,097 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: Awarded on May 23, 2024 pursuant to the 2023 Plan. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F7 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F7 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:08 UTC |
Morrison SusanEVP & Chief Admin. Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,503 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000060 · wk-form4_1779221291.xml · derivative · entry 8 Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,503 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Awarded on May 25, 2023 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). F4 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F5 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F5 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:08 UTC |
Morrison SusanEVP & Chief Admin. Officer
|
GrantCommon Stock | 1,336 | $10.90 | $14,562.40 |
DisclosureSEC source: 0001438133-26-000060 · wk-form4_1779221291.xml · nonDerivative · entry 7 Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,770 F2 · kind: The reporting person is voluntarily reporting the acquisition of shares of common stock pursuant to the Tandem Diabetes Care, Inc. Amended and Restated 2013 Employee Stock Purchase Plan (ESPP), for the ESPP purchase period of November 18, 2025, through May 15, 2026. This transaction is also exempt under Rule 16b-3(c). Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:08 UTC |
Morrison SusanEVP & Chief Admin. Officer
|
Tax withholdingCommon Stock | 1,980 | $12.82 | $25,383.60 |
DisclosureSEC source: 0001438133-26-000060 · wk-form4_1779221291.xml · nonDerivative · entry 6 Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,434 F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:08 UTC |
Morrison SusanEVP & Chief Admin. Officer
|
Exercise / conversionCommon Stock | 6,923 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000060 · wk-form4_1779221291.xml · nonDerivative · entry 5 Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,414 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:08 UTC |
Morrison SusanEVP & Chief Admin. Officer
|
Tax withholdingCommon Stock | 314 | $12.82 | $4,025.48 |
DisclosureSEC source: 0001438133-26-000060 · wk-form4_1779221291.xml · nonDerivative · entry 4 Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,491 F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:08 UTC |
Morrison SusanEVP & Chief Admin. Officer
|
Exercise / conversionCommon Stock | 1,097 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000060 · wk-form4_1779221291.xml · nonDerivative · entry 3 Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,805 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:08 UTC |
Morrison SusanEVP & Chief Admin. Officer
|
Tax withholdingCommon Stock | 430 | $12.82 | $5,512.60 |
DisclosureSEC source: 0001438133-26-000060 · wk-form4_1779221291.xml · nonDerivative · entry 2 Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,708 F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:08 UTC |
Morrison SusanEVP & Chief Admin. Officer
|
Exercise / conversionCommon Stock | 1,503 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000060 · wk-form4_1779221291.xml · nonDerivative · entry 1 Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,138 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:02 UTC |
Novara Mark DavidEVP & CHIEF COMMERCIAL OFFICER
|
Exercise / conversionRestricted Stock Unit · Derivative | 10,496 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000054 · wk-form4_1779220921.xml · derivative · entry 6 Novara Mark David · CIK 0002000342 · EVP & CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,992 Underlying: Common Stock · 10,496 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Awarded on May 30, 2025 pursuant to the 2023 Plan. F3 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F6 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2026, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F6 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2026, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:02 UTC |
Novara Mark DavidEVP & CHIEF COMMERCIAL OFFICER
|
Exercise / conversionRestricted Stock Unit · Derivative | 76 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000054 · wk-form4_1779220921.xml · derivative · entry 5 Novara Mark David · CIK 0002000342 · EVP & CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 304 Underlying: Common Stock · 76 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Awarded on May 23, 2024 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). F3 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F4 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F4 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:02 UTC |
Novara Mark DavidEVP & CHIEF COMMERCIAL OFFICER
|
Tax withholdingCommon Stock | 7,854 | $12.82 | $100,688.28 |
DisclosureSEC source: 0001438133-26-000054 · wk-form4_1779220921.xml · nonDerivative · entry 4 Novara Mark David · CIK 0002000342 · EVP & CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,317 F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:02 UTC |
Novara Mark DavidEVP & CHIEF COMMERCIAL OFFICER
|
Exercise / conversionCommon Stock | 10,496 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000054 · wk-form4_1779220921.xml · nonDerivative · entry 3 Novara Mark David · CIK 0002000342 · EVP & CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,171 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:02 UTC |
Novara Mark DavidEVP & CHIEF COMMERCIAL OFFICER
|
Tax withholdingCommon Stock | 57 | $12.82 | $730.74 |
DisclosureSEC source: 0001438133-26-000054 · wk-form4_1779220921.xml · nonDerivative · entry 2 Novara Mark David · CIK 0002000342 · EVP & CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,675 F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:02 UTC |
Novara Mark DavidEVP & CHIEF COMMERCIAL OFFICER
|
Exercise / conversionCommon Stock | 76 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000054 · wk-form4_1779220921.xml · nonDerivative · entry 1 Novara Mark David · CIK 0002000342 · EVP & CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,732 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:06 UTC |
Sheridan John FDirector · PRESIDENT & CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 39,735 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000058 · wk-form4_1779221206.xml · derivative · entry 10 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,471 Underlying: Common Stock · 39,735 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · security: Awarded on May 30, 2025 pursuant to the 2023 Plan. F4 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F9 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2026, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F9 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2026, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:06 UTC |
Sheridan John FDirector · PRESIDENT & CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 5,982 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000058 · wk-form4_1779221206.xml · derivative · entry 9 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,929 Underlying: Common Stock · 5,982 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: Awarded on May 23, 2024 pursuant to the 2023 Plan, as amended. F4 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F7 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F7 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:06 UTC |
Sheridan John FDirector · PRESIDENT & CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 5,472 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000058 · wk-form4_1779221206.xml · derivative · entry 8 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,472 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Awarded on May 25, 2023 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). F4 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F5 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F5 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:06 UTC |
Sheridan John FDirector · PRESIDENT & CEO
|
GrantCommon Stock | 1,336 | $10.90 | $14,562.40 |
DisclosureSEC source: 0001438133-26-000058 · wk-form4_1779221206.xml · nonDerivative · entry 7 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,443 F2 · kind: The reporting person is voluntarily reporting the acquisition of shares of common stock pursuant to the Tandem Diabetes Care, Inc. Amended and Restated 2013 Employee Stock Purchase Plan (ESPP), for the ESPP purchase period of November 18, 2025, through May 15, 2026. This transaction is also exempt under Rule 16b-3(c). Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:06 UTC |
Sheridan John FDirector · PRESIDENT & CEO
|
Tax withholdingCommon Stock | 18,944 | $12.82 | $242,862.08 |
DisclosureSEC source: 0001438133-26-000058 · wk-form4_1779221206.xml · nonDerivative · entry 6 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 151,107 F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:06 UTC |
Sheridan John FDirector · PRESIDENT & CEO
|
Exercise / conversionCommon Stock | 39,735 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000058 · wk-form4_1779221206.xml · nonDerivative · entry 5 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,051 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:06 UTC |
Sheridan John FDirector · PRESIDENT & CEO
|
Tax withholdingCommon Stock | 3,044 | $12.82 | $39,024.08 |
DisclosureSEC source: 0001438133-26-000058 · wk-form4_1779221206.xml · nonDerivative · entry 4 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,316 F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:06 UTC |
Sheridan John FDirector · PRESIDENT & CEO
|
Exercise / conversionCommon Stock | 5,982 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000058 · wk-form4_1779221206.xml · nonDerivative · entry 3 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 133,360 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:06 UTC |
Sheridan John FDirector · PRESIDENT & CEO
|
Tax withholdingCommon Stock | 2,785 | $12.82 | $35,703.70 |
DisclosureSEC source: 0001438133-26-000058 · wk-form4_1779221206.xml · nonDerivative · entry 2 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 127,378 F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:06 UTC |
Sheridan John FDirector · PRESIDENT & CEO
|
Exercise / conversionCommon Stock | 5,472 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000058 · wk-form4_1779221206.xml · nonDerivative · entry 1 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,163 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 15, 2026 Filed Apr 17, 2026 20:10 UTC |
Kyrillos Jean-ClaudeEVP & Chief Operating Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 3,636 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000040 · wk-form4_1776456641.xml · derivative · entry 3 Kyrillos Jean-Claude · CIK 0001804186 · EVP & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,181 Underlying: Common Stock · 3,636 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Awarded on July 15, 2024 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). F3 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F4 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 7/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F4 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 7/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| April 15, 2026 Filed Apr 17, 2026 20:10 UTC |
Kyrillos Jean-ClaudeEVP & Chief Operating Officer
|
Tax withholdingCommon Stock | 1,926 | $20.66 | $39,791.16 |
DisclosureSEC source: 0001438133-26-000040 · wk-form4_1776456641.xml · nonDerivative · entry 2 Kyrillos Jean-Claude · CIK 0001804186 · EVP & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,772 F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| April 15, 2026 Filed Apr 17, 2026 20:10 UTC |
Kyrillos Jean-ClaudeEVP & Chief Operating Officer
|
Exercise / conversionCommon Stock | 3,636 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000040 · wk-form4_1776456641.xml · nonDerivative · entry 1 Kyrillos Jean-Claude · CIK 0001804186 · EVP & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,698 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 17, 2026 Filed Mar 18, 2026 20:06 UTC |
Novara Mark DavidEVP & CHIEF COMMERCIAL OFFICER
|
SaleCommon Stock | 187 | $23.05 | $4,310.35 |
DisclosureSEC source: 0001438133-26-000023 · wk-form4_1773864360.xml · nonDerivative · entry 3 Novara Mark David · CIK 0002000342 · EVP & CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,656 F2 · kind: The shares were sold, pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 4, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.